Abstract:Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder. It is characterized by the progressive loss of dopaminergic (DAnergic) neurons in the substantia nigra and decreased dopamine (DA) levels, which lead to both motor and non-motor symptoms. Conventional PD treatments aim to alleviate symptoms, but do not delay disease progression. PD gene therapy offers a promising approach to improving current treatments, with the potential to alleviate significant PD symptoms and cause fewer adverse effects than conventional therapies. DA replacement approaches and DA enzyme expression do not slow disease progression. However, DA replacement gene therapies, such as adeno-associated virus (AAV)–glutamic acid decarboxylase (GAD) and L-amino acid decarboxylase (AADC) gene therapies, which increase DA transmitter levels, have been demonstrated to be safe and efficient in early-phase clinical trials. Disease-modifying strategies, which aim to slow disease progression, appear to be potent. These include therapies targeting downstream pathways, neurotrophic factors, and midbrain DAnergic neuronal factors, all of which have shown potential in preclinical and clinical trials. These approaches focus on maintaining the integrity of DAnergic neurons, not just targeting the DA transmitter level itself. In particular, critical midbrain developmental and maintenance factors, such as Nurr1 and Foxa2, can interact synergistically with neighboring glia, in a paracrine mode of action, to protect DAnergic neurons against various toxic factors. Similar outcomes could be achieved by targeting both DAnergic neurons and glial cells with other candidate gene therapies, but in-depth research is needed. Neurotrophic factors, such as neurturin, the glial-cell-line-derived neurotrophic factor (GDNF), the brain-derived neurotrophic factor (BDNF), and the vascular endothelial growth factor (VEGF), are also being investigated for their potential to support DAnergic neuron survival. Additionally, gene therapies targeting key downstream pathways, such as the autophagy–lysosome pathway, mitochondrial function, and endoplasmic reticulum (ER) stress, offer promising avenues. Gene editing and delivery techniques continue to evolve, presenting new opportunities to develop effective gene therapies for PD.

CRISPR-Cas9-Based Technology and Its Relevance to Gene Editing in Parkinson's Disease

Utilization of the CRISPR-Cas9 Gene Editing System to Dissect Neuroinflammatory and Neuropharmacological Mechanisms in Parkinson’s Disease

Clustered Regularly Interspaced Short Palindromic Repeats As an Advanced Treatment for Parkinson's Disease

Exploring Parkinson-associated kinases for CRISPR/Cas9-based gene editing: beyond alpha-synuclein

CRISPR/Cas9 assisted stem cell therapy in Parkinson's disease

CRISPR-Cas9 through AAV delivery system as a gene therapy in Parkinson’s disease

Next Generation Precision Medicine: CRISPR-mediated Genome Editing for the Treatment of Neurodegenerative Disorders

Genome Editing in iPSC-Based Neural Systems: From Disease Models to Future Therapeutic Strategies

Advancements in CRISPR-Based Therapies for Genetic Modulation in Neurodegenerative Disorders

From lab bench to hope: a review of gene therapies in clinical trials for Parkinson's disease and challenges

Applications of CRISPR-Cas9 in Alzheimer’s Disease and Related Disorders

CRISPR/Cas9 gene editing: New hope for Alzheimer's disease therapeutics

Applications of CRISPR-Cas9 in Alzheimer's Disease and Related Disorders

The efficacy and safety of gene therapy approaches in Parkinson's disease: A systematic review

Interrogating Parkinson's disease associated redox targets: Potential application of CRISPR editing

Prospects for polymer therapeutics in Parkinson's disease and other neurodegenerative disorders

Redefining Parkinson’s Disease Research Using Induced Pluripotent Stem Cells

Extracellular vesicle and CRISPR gene therapy: Current applications in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and Huntington's disease

Advancements in Genetic and Biochemical Insights: Unraveling the Etiopathogenesis of Neurodegeneration in Parkinson's Disease

Gene Therapy for Parkinson's Disease Using Midbrain Developmental Genes to Regulate Dopaminergic Neuronal Maintenance

CRISPR-Based Gene Editing Techniques in Pediatric Neurological Disorders